美股新聞 標題聯播 · 近 24 小時 337 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · OABI近 30 天 4 則 · 第 1 / 1 頁
- OmniAb to Host Investor & Analyst Day on October 6, 2026
- Is OmniAb (OABI)’s Eli Lilly (LLY) Partnership a Game Changer for OABI?
- VERAXA Biotech (VRXA), Secarna Partnership Milestone Opens New Potential Market for Conjugation Technology
- OmniAb to Participate in Upcoming Investor Conferences
- Why Eli Lilly (LLY) Stock Is Up Today
- Eli Lilly (LLY) Adds Neuroscience And Lung Cancer Research Deals
- OmniAb Jumps 18% as Lilly Deal Lifts Cash Outlook
- Top Midday Gainers
- OmniAb lifts 2026 cash outlook following licensing momentum
- OmniAb Raises 2026 Financial Guidance
- OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company
- OmniAb (OABI) Q2 2026 Earnings Call Transcript
- OmniAb Q2 Earnings Call Highlights
- OmniAb Inc (OABI) (Q2 2026) Earnings Call Highlights: Revenue Surges 243% as Two Programs Leap ...
- OmniAb, Inc. (OABI) Reports Q2 Loss, Beats Revenue Estimates
- OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights
- VERAXA Biotech (VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies
- VERAXA Biotech (VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration
- VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。